NASDAQ:SGEN - Seattle Genetics Stock Price, Forecast & News

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

Seattle Genetics, Inc. (NASDAQ:SGEN) announced its quarterly earnings data on Tuesday, October, 29th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.19. The biotechnology company earned $213.26 million during the quarter, compared to analysts' expectations of $211.85 million. Seattle Genetics had a negative net margin of 37.97% and a negative return on equity of 19.17%. The company's revenue for the quarter was up 25.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.42) EPS. View Seattle Genetics' Earnings History.

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Seattle Genetics.

19 equities research analysts have issued twelve-month target prices for Seattle Genetics' shares. Their forecasts range from $74.00 to $140.00. On average, they anticipate Seattle Genetics' stock price to reach $111.47 in the next twelve months. This suggests that the stock has a possible downside of 2.1%. View Analyst Price Targets for Seattle Genetics.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seattle Genetics.

Headlines about SGEN stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Seattle Genetics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Seattle Genetics.

Some companies that are related to Seattle Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Seattle Genetics investors own include Immunomedics (IMMU), Celgene (CELG), Gilead Sciences (GILD), Incyte (INCY), Netflix (NFLX), Alibaba Group (BABA), Alexion Pharmaceuticals (ALXN), NVIDIA (NVDA), Micron Technology (MU) and AbbVie (ABBV).

Seattle Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.92%), First Trust Advisors LP (0.54%), Point72 Asset Management L.P. (0.43%), Pictet Asset Management Ltd. (0.39%), Manning & Napier Group LLC (0.35%) and Sumitomo Mitsui Trust Holdings Inc. (0.28%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, David W Gryska, Jean I Liu, Jonathan G Drachman, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

SGEN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Manning & Napier Group LLC, Russell Investments Group Ltd., Fjarde AP Fonden Fourth Swedish National Pension Fund, Squarepoint Ops LLC, Sumitomo Mitsui Trust Holdings Inc., Stifel Financial Corp and Lagoda Investment Management L.P.. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

SGEN stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Pictet Asset Management Ltd., State of New Jersey Common Pension Fund D, Point72 Asset Management L.P., California Public Employees Retirement System, Castleark Management LLC, CIBC Asset Management Inc and Maverick Capital Ltd.. View Insider Buying and Selling for Seattle Genetics.

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SGEN stock can currently be purchased for approximately $113.87.

Seattle Genetics has a market capitalization of $19.52 billion and generates $654.70 million in revenue each year. The biotechnology company earns $-222,690,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Seattle Genetics employs 1,302 workers across the globe.View Additional Information About Seattle Genetics.

The official website for Seattle Genetics is http://www.seattlegenetics.com/.

Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]